



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: December 12, 2008

To: Primary Clinical Research Associates

From: Alicia Elsing
Research Protocol Specialist III

Re: N0821, A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age \geq 70 yrs) with Good Performance Status (PS $<$ 2)

The above study is now active.

A protocol and forms packet are enclosed. You may submit this protocol to your IRB for approval.

Please note that this study was approved by the National Cancer Institute on December 4, 2008.

If you have any questions, please feel free to contact me at elsing.alicia@mayo.edu or 507-538-3893.

Enclosure